Mod GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
For just as a man has a body that is no different in principle from that of an animal, so also his psychology has a whole series of lower storeys in which the spectres from humanity's past epochs still dwell, then the animal souls from the age of Pithecanthropus and the hominids, then the "psyche" of the cold-blooded saurian. Jung's notion of different evolutionary layers in the human mind has been compared with the work of neuroscientist Jaak Panksepp, particularly as outlined in his book The Archaeology of Mind: Neuroevolutionary Origins of Human Emotions. Of these affinities it has been suggested that 'Jung and Panksepp have, independently it seems, developed similar metaphors of an archeologically layered psyche in which jewels and treasures are discoverable in the deepest phylogenetically ancient regions of the brain – for Jung they are archetypal structures for Panksepp cross-species homologies.' Significantly, in a 2017 article entitled "The Affective Core of the Self: A Neuro-Archetypical Perspective on the Foundations of Human (and Animal) Subjectivity", when noting Jung's belief that archetypes may be related to evolutionarily ancient subcortical brain systems, Panksepp and colleagues wrote that "such assertions by Jung were not only quite farsighted, but they actually open ways to connect his theory of the psyche with the most advanced scientific theories and discoveries of our day."
Pennington was born on October 8, 1872, in Nashville, Tennessee, to Henry and Sarah Malony Pennington. Shortly after her birth, her parents moved to Philadelphia to be closer to her mother's Quaker relatives. She became interested in chemistry at the age of 12 after reading a library book on medicinal chemistry. She walked to the University of Pennsylvania and asked a professor for help with the terminology she did not understand. She was told to come back when she was older. She entered the University of Pennsylvania in 1890 and completed the requirements for a B.S. degree in chemistry with minors in botany and zoology in 1892. However, since the University of Pennsylvania did not grant degrees to women at this time, she was given a certificate of proficiency instead of a degree. Pennington received her Ph.D. from the University of Pennsylvania in 1895. Her thesis was entitled "Derivatives of Columbium and Tantalum." From 1895 to 1896, she was a university fellow in botany at the University of Pennsylvania. She was a fellow in physiological chemistry at Yale University from 1897 to 1899, and conducted research with Lafayette Mendel and Russell Henry Chittenden.
=== Pharmacokinetics === DET demonstrates significant resistance to metabolism by monoamine oxidase A (MAO-A) compared to DMT. This may be due to the increased steric bulk of the N-ethyl substituents relative to the respective methyl groups of DMT which results in metabolic stability sufficient for oral activity. This is also true for many other tryptamines with larger nitrogen substituents. The drug similarly to DMT is rapidly absorbed from the intraperitoneal cavity and quickly distributed through plasma, liver and brain. Most of the substance had disappeared from the aforementioned tissues 30 minutes from administration, except in the brain, where it could still be detected at 60 minutes. Likewise to DMT the substance is metabolized through 6-hydroxylation and N-dealkylation to form the corresponding intermediates. These metabolites were found to be excreted in urine of about 20% of the administered dose as the glucoronide conjugate, of which the parent compound can be detected by chromatographic analysis at low concentrations (3–5%). Hepatic 6-hydroxylation of the indole ring, yields a minor, psychoactively inactive metabolite 6-hydroxy-DET (6-HO-DET) in similar concentration, with additional hydroxylation possible at alternative positions. Repeated administration of DET, or second exposure one to two weeks after the first, resulted in significant metabolic changes. The unchanged drug excreted after a later exposure was significantly lower, while the excretion of the metabolites which were measured in this case were higher than at the first exposure to DET.
Sources: en.wikipedia.org
Additionally, FLAG-tags may be used in tandem, commonly the 3xFLAG peptide: DYKDHD-G-DYKDHD-I-DYKDDDDK (with the final tag encoding an enterokinase cleavage site). FLAG-tag can be fused to the C-terminus or the N-terminus of a protein, or inserted within a protein. Some commercially available antibodies (e.g., M1/4E11) recognize the epitope only when FLAG-tag is present at the N-terminus. However, other available antibodies (e.g., M2) are position-insensitive. The tyrosine residue in the FLAG-tag can be sulfated when expressed on certain secreted proteins, which can affect antibody recognition of the FLAG epitope. The FLAG-tag can be used in conjunction with other affinity tags, for example a polyhistidine tag (His-tag), HA-tag or myc-tag.
, contains the bulk modulus K. If K is frequency-independent, then the liquid behaves as a linear medium, so that sound propagates without dissipation or mode coupling. In reality, all liquids show some dispersion: with increasing frequency, K crosses over from the low-frequency, liquid-like limit
According to Rubio, the first phase is about the stabilization of the country after the strikes and stopping it from "descending into chaos," including refining and selling up to 50 million barrels of seized Venezuelan crude oil, adding that "that money will then be handled in such a way that we will control how it is disbursed in a way that benefits the Venezuelan people, not corruption, not the regime, so we have a lot of leverage to move on the stabilization front." During the second phase of recovery, the goal is to assure foreign companies have access to Venezuelan oil trade and "also, at the same time, begin to create the process of reconciliation nationally within Venezuela, so that the opposition forces can be amnestied and released from prisons or brought back to the country, and begin to rebuild civil society." Rubio added that the final and third phase consist on overseeing a transition, "this will be a process of transition. In the end, it will be up to the Venezuelan people to transform their country." Trump stated there was an agreement by Venezuela to deliver a few months' worth of oil to the US, intimating that other steps, such as the freeing of political detainees and a role for the exiled opposition, might be next. However, President Rodríguez denied the existence of a deal, saying "no external agent" was dictating her decisions. On 8 January, the US Senate voted 52 to 47 to advance a war resolution that aimed to block the president's use of the US military to engage in military action within or against Venezuela unless authorized by Congress.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.